NCT07453225

Empirical Radioactive Iodine Therapy in DTC

Efficacy of Empirical Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma Patients With Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) Syndrome

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.

Detailed description

Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) accounting for more than 90% of all thyroid cancers. The standard treatment of patients with (DTC) consists of surgery followed by radioactive iodine therapy (RAI).The response to initial therapy is usually assessed by serum thyroglobulin (Tg) levels and neck ultrasonography (US) according to American Thyroid Association (ATA) guidelines. Some patients with elevated serum Tg levels don't not show evidence of structural disease during follow up. Diagnostic iodine-131 (131I) whole body scan (WBS) has been largely used for assessment of disease status. Empiric RAI administration can be considered in patients with elevated Tg values after the first treatment and without evidence of structural disease (negative iodine scintigraphy). Our approach is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.

Conditions

• Differentiated Thyroid Cancer

Interventions

Type	Name	Description
DRUG	Radioactive Iodine Therapy	empirical dose of RAI

Timeline

• Start date: 2026-04-01
• Primary completion: 2028-04-01
• Completion: 2028-07-01
• First posted: 2026-03-05
• Last updated: 2026-03-05